Airborne Purchased by GF Capital

Mon Oct 12, 2009 7:00am EDT

* Reuters is not responsible for the content in this press release.

MINNEAPOLIS--(Business Wire)--
Airborne, Inc., maker of dietary supplements that support immune health, today
announced that it has been purchased by GF Capital Private Equity Fund, LP, a
New York City-based private equity firm. Terms of the deal were not disclosed.
Stockton Road Capital, LLC, advised and partnered with GF Capital with respect
to this investment. 

Airborne is a dietary supplement that was created by a school teacher to help
support her immune system. The supplement is a proprietary blend of 17 vitamins,
minerals and herbs. The key ingredients in Airborne have been shown to help
support the immune system as shown in scientific studies and medical
journals.Airborne products can be found in food, drug and mass retailers across
the United States and Canada. 

GF Capital has named Martha (Marti) A. Morfitt as Airborne`s new chief executive
officer. Ms. Morfitt most recently served as chief executive officer and a
director of CNS, Inc., a publicly traded marketer of consumer health care
products. During her nine-year tenure, Ms. Morfitt and her team successfully
completed a performance turnaround at CNS, returning the company to
profitability and transforming it into a growing consumer health products
company with flagship brands that include Breathe Right nasal strips and
FiberChoice daily fiber supplement brands. CNS was sold to GlaxoSmithKline in
December 2006. 

"This is an exciting time to step into this role for Airborne," said Ms.
Morfitt. "The company is a leader in nutritional supplements that support immune
health, an increasingly important category as consumers come to appreciate the
benefits of a healthy lifestyle. Our management team and GF Capital are
committed to the long-term, profitable growth and expansion of the Airborne
brand." 

Said Neil Shapiro, co-founder and managing director GF Capital, "Airborne
occupies a unique place in the nutritional supplement market. We firmly believe
in the company and its products, and believe that there`s tremendous opportunity
for us to grow together. As CEO, Marti has a proven ability to lead companies to
profitable growth, expanding their brands and product offerings in the process.
We have the utmost confidence in the Airborne team." 

Sawaya Segalas & Co., LLC[1], a leading consumer investment banking firm, acted
as exclusive financial advisor to Airborne Health, Inc., in connection with the
transaction. 

About GF Capital

GF Capital Management & Advisors, LLC, makes private equity and real estate
investments, and provides comprehensive wealth management and financial advisory
services to its clients. The senior investment team at GF Capital has over two
decades of experience investing its own capital as principals, as well as
capital on behalf of clients in private equity transactions. The GF Capital
Private Equity Fund, LP, principally makes growth capital investments in the
branded consumer products, and media and entertainment sectors. 

About Stockton Road Capital

Stockton Road Capital is a specialized private equity investment firm and
advisor that focuses on the consumer products industry. Visit the firm online
at: www.stocktonroadcapital.com. 

About Airborne

Airborne develops and sells innovative dietary supplements throughout the United
States and Canada. Our Airborne health formula is designed to support customers`
immune systems through its unique combination of vitamins, nutrients and
proprietary blend of herbal extracts. Headquartered in Minneapolis, Minn., with
facilities in Carmel, Calif., visit Airborne online at www.airbornehealth.com. 

[1] Securities offered through Sawaya Segalas Securities, LLC.

At Airborne:
Marti Morfitt, CEO, 612-235-3800
mamorfitt@airbornehealth.com
or
At GF Capital:
Neil Shapiro, 212-433-1233
nshapiro@gfcap.com
or
At Padilla Speer Beardsley:
Matt Sullivan, 612-455-1709
msullivan@psbpr.com

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.